Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. more
Time Frame | RSLS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.59% | 0.31% | -1.26% |
1-Month Return | -0.02% | 0.6% | -4.16% |
3-Month Return | -12.9% | -9.44% | -0.46% |
6-Month Return | -64.71% | -5.15% | 3.58% |
1-Year Return | -67.07% | 0.33% | 22.47% |
3-Year Return | -99.9% | 4.53% | 25.13% |
5-Year Return | -99.91% | 35.98% | 77.7% |
10-Year Return | -100% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 15.09M | 11.30M | 13.60M | 11.24M | 8.68M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":74.88,"profit":true},{"date":"2021-12-31","value":90.13,"profit":true},{"date":"2022-12-31","value":74.49,"profit":true},{"date":"2023-12-31","value":57.51,"profit":true}] |
Cost of Revenue | 5.78M | 5.04M | 5.25M | 4.44M | 3.13M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":87.09,"profit":true},{"date":"2021-12-31","value":90.8,"profit":true},{"date":"2022-12-31","value":76.73,"profit":true},{"date":"2023-12-31","value":54.11,"profit":true}] |
Gross Profit | 9.30M | 6.26M | 8.35M | 6.80M | 5.55M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.3,"profit":true},{"date":"2021-12-31","value":89.72,"profit":true},{"date":"2022-12-31","value":73.1,"profit":true},{"date":"2023-12-31","value":59.62,"profit":true}] |
Gross Margin | 61.67% | 55.42% | 61.38% | 60.52% | 63.93% | [{"date":"2019-12-31","value":96.46,"profit":true},{"date":"2020-12-31","value":86.69,"profit":true},{"date":"2021-12-31","value":96.01,"profit":true},{"date":"2022-12-31","value":94.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 25.19M | 18.72M | 36.10M | 33.88M | 20.19M | [{"date":"2019-12-31","value":69.79,"profit":true},{"date":"2020-12-31","value":51.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.86,"profit":true},{"date":"2023-12-31","value":55.92,"profit":true}] |
Operating Income | (15.89M) | (12.46M) | (27.75M) | (27.08M) | (14.64M) | [{"date":"2019-12-31","value":-1588700000,"profit":false},{"date":"2020-12-31","value":-1245700000,"profit":false},{"date":"2021-12-31","value":-2774900000,"profit":false},{"date":"2022-12-31","value":-2707800000,"profit":false},{"date":"2023-12-31","value":-1463900000,"profit":false}] |
Total Non-Operating Income/Expense | (59.66M) | (11.40M) | (35.12M) | (4.79M) | 3.15M | [{"date":"2019-12-31","value":-1892.29,"profit":false},{"date":"2020-12-31","value":-361.66,"profit":false},{"date":"2021-12-31","value":-1113.92,"profit":false},{"date":"2022-12-31","value":-152.05,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (75.10M) | (21.81M) | (62.04M) | (46.59M) | (11.34M) | [{"date":"2019-12-31","value":-7510000000,"profit":false},{"date":"2020-12-31","value":-2181100000,"profit":false},{"date":"2021-12-31","value":-6203900000,"profit":false},{"date":"2022-12-31","value":-4659400000,"profit":false},{"date":"2023-12-31","value":-1133500000,"profit":false}] |
Income Taxes | (893.00K) | (181.00K) | (106.00K) | (380.00K) | 52.00K | [{"date":"2019-12-31","value":-1717.31,"profit":false},{"date":"2020-12-31","value":-348.08,"profit":false},{"date":"2021-12-31","value":-203.85,"profit":false},{"date":"2022-12-31","value":-730.77,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (74.21M) | (21.63M) | (61.93M) | (46.21M) | (11.39M) | [{"date":"2019-12-31","value":-7420700000,"profit":false},{"date":"2020-12-31","value":-2163000000,"profit":false},{"date":"2021-12-31","value":-6193300000,"profit":false},{"date":"2022-12-31","value":-4621400000,"profit":false},{"date":"2023-12-31","value":-1138700000,"profit":false}] |
Income From Continuous Operations | (74.21M) | (21.63M) | (61.93M) | (46.21M) | (26.16M) | [{"date":"2019-12-31","value":-7420700000,"profit":false},{"date":"2020-12-31","value":-2163000000,"profit":false},{"date":"2021-12-31","value":-6193300000,"profit":false},{"date":"2022-12-31","value":-4621400000,"profit":false},{"date":"2023-12-31","value":-2615800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (74.21M) | (21.63M) | (61.93M) | (46.21M) | (11.39M) | [{"date":"2019-12-31","value":-7420700000,"profit":false},{"date":"2020-12-31","value":-2163000000,"profit":false},{"date":"2021-12-31","value":-6193300000,"profit":false},{"date":"2022-12-31","value":-4621400000,"profit":false},{"date":"2023-12-31","value":-1138700000,"profit":false}] |
EPS (Diluted) | (1.10K) | (238.50) | (190.50) | (81.59) | (3.55) | [{"date":"2019-12-31","value":-110250,"profit":false},{"date":"2020-12-31","value":-23850,"profit":false},{"date":"2021-12-31","value":-19050,"profit":false},{"date":"2022-12-31","value":-8159,"profit":false},{"date":"2023-12-31","value":-355,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RSLS | |
---|---|
Cash Ratio | 0.18 |
Current Ratio | 1.33 |
Quick Ratio | 0.60 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RSLS | |
---|---|
ROA (LTM) | -63.46% |
ROE (LTM) | -184.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RSLS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.74 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.26 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RSLS | |
---|---|
Trailing PE | 0.07 |
Forward PE | NM |
P/S (TTM) | 0.42 |
P/B | 2.45 |
Price/FCF | NM |
EV/R | 0.38 |
EV/Ebitda | NM |
ReShape Lifesciences Inc (RSLS) share price today is $4.66
Yes, Indians can buy shares of ReShape Lifesciences Inc (RSLS) on Vested. To buy ReShape Lifesciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RSLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of ReShape Lifesciences Inc (RSLS) via the Vested app. You can start investing in ReShape Lifesciences Inc (RSLS) with a minimum investment of $1.
You can invest in shares of ReShape Lifesciences Inc (RSLS) via Vested in three simple steps:
The 52-week high price of ReShape Lifesciences Inc (RSLS) is $16.6. The 52-week low price of ReShape Lifesciences Inc (RSLS) is $4.
The price-to-earnings (P/E) ratio of ReShape Lifesciences Inc (RSLS) is 0.0661
The price-to-book (P/B) ratio of ReShape Lifesciences Inc (RSLS) is 2.45
The dividend yield of ReShape Lifesciences Inc (RSLS) is 0.00%
The market capitalization of ReShape Lifesciences Inc (RSLS) is $3.40M
The stock symbol (or ticker) of ReShape Lifesciences Inc is RSLS